---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-23-028730"
form_type: "8-K"
ticker: "XFOR"
cik: "0001501697"
company_name: "X4 Pharmaceuticals, Inc"
filed_at: "2023-08-10T23:59:59+00:00"
generated_at: "2026-06-11T17:17:18.717809+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# X4 Pharma Q2 net loss $55.7M; WHIM NDA on track; chronic neutropenia data promising

## Summary
- Net loss of $55.7M in Q2 2023 includes $29.9M non-cash warrant adjustment; cash $142.3M at June 30.
- NDA submission for mavorixafor in WHIM syndrome on track for early 2H 2023; potential US approval in 1H 2024.
- Preliminary Phase 2 chronic neutropenia data: mavorixafor increased ANC and enabled G-CSF dose reductions in 3 patients.
- Raised ~$65M via PIPE in May 2023; post-quarter expanded debt facility to $115M with $22.5M initial drawdown.
- Appointed Dr. Christophe Arbet-Engels as Chief Medical Officer; new mavorixafor composition-of-matter patent through 2038.

## SEC filing metadata
- accession: 0001628280-23-028730
- form_type: 8-K
- ticker: XFOR
- cik: 0001501697
- company_name: X4 Pharmaceuticals, Inc
- filed_at: 2023-08-10T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1501697/000162828023028730/0001628280-23-028730-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1501697/000162828023028730/xfor-20230810.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-23-028730
- JSON: https://secwatch.observer/filing/0001628280-23-028730.json
- Plain text: https://secwatch.observer/filing/0001628280-23-028730.txt

## Key facts
- Earnings Releases
  X4 Pharmaceuticals, Inc reported financial results for the second quarter ended June 30, 2023.
  - Period: the second quarter ended June 30, 2023
  - Result: reported results
  source text: On August 10, 2023, X4 Pharmaceuticals, Inc. (the “Company”) issued a press release announcing its financial results and other business highlights for the second quarter ended June 30, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1501697/000162828023028730/0001628280-23-028730-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.